Short answer
iRhythm Holdings, Inc. (IRTC) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $222M (up 14.9% year over year) with net income of −$30M.
Q3 2026 key financials · XBRL
- Revenue
- $222M
- +14.9% YoY · −1.2% QoQ
- Net income
- −$30M
- −472.7% YoY · −7734.9% QoQ
- Operating margin
- -14.7%
- Gross margin
- 74.2%
- EPS (diluted)
- −$0.91
- −468.8% YoY · −9000.0% QoQ
Source: XBRL data from the iRhythm Holdings, Inc. (IRTC) Q3 2026 10-Q on SEC EDGAR. USD.
iRhythm Holdings, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $221.6M, up 15% YoY from $192.9M, driven by higher Zio monitor and Zio AT volumes
- Gross margin 74.2% vs 71.1% YoY, supported by $3.1M tariff refunds and manufacturing efficiencies
- Net loss $29.9M vs $5.2M, including $49.8M litigation settlements and $6.6M transformation costs
- Cash $394.7M, marketable securities $166.0M, operating cash flow $29.3M vs $54.7M
- VitalConnect acquisition closed October 5 for approximately $237.5M cash, with macroeconomic pressure and payer reimbursement challenges remaining headwinds
Risk Factors
- New acquisition risk: VitalConnect acquired October 5, 2026, creating integration challenges across regulatory, quality, clinical, and billing functions
- Most materially updated regulatory risk: FDA QMSR effective February 2, 2026, creating uncertainty around future device-quality inspections
- Legal and compliance risk: DOJ civil investigative demand dated December 12, 2025, seeks information on Zio AT and related reimbursement claims
- Near-term operational risk: AI-enabled payer audits increase billing scrutiny and could delay or reduce revenue and accounts receivable
- Financial risk: Medicare represented approximately 26% of total revenue during the three and nine months ended September 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other iRhythm Holdings, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.